Protocol Ledger

NCT07519902 · Phase III · RECRUITING

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

Interventional Phase III clinical trial protocol NCT07519902 sponsored by Dompé Farmaceutici S.p.A in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-02 Enrollment: 150 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07519902
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)150 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07519902
Protocol FieldVerified Registry Value
NCT IdentifierNCT07519902
Consolidated Lead SponsorDompé Farmaceutici S.p.A
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment150 participants (ESTIMATED)
Registered Start Date2026-06-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI